Rucaparib
Rucaparib is a pharmaceutical drug with 55 clinical trials. Currently 9 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 30 completed trials
Phase Distribution
Phase Distribution
21
Early Stage
26
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
69.8%
30 of 43 finished
30.2%
13 ended early
9
trials recruiting
55
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Pan Tumor Rollover Study
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Clinical Trials (55)
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Pan Tumor Rollover Study
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 55